SPINK7/ECRG2 (SPINK7)
(Serine Peptidase Inhibitor, Kazal Type 7 (SPINK7))
Bindungsspezifität
C-Term
Reaktivität
Human, Maus, Ratte
Wirt
Huhn
Klonalität
Polyklonal
Konjugat
Dieser SPINK7/ECRG2 Antikörper ist unkonjugiert
Applikation
ELISA, Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Spezifität
ECRG2 antibody is predicted to not cross-react with other ECRG family members
Aufreinigung
ECRG2 Antibody is affinity chromatography purified via peptide column.
Immunogen
ECRG2 antibody was raised against a 16 amino acid synthetic peptide near the carboxy terminus of human ECRG2. The immunogen is located within the last 50 amino acids of ECRG2.
SPINK7
Reaktivität: Human, Maus
WB, IF (cc), IF (p)
Wirt: Kaninchen
Polyclonal
Cy5
Applikationshinweise
ECRG2 antibody can be used for detection of ECRG2 by Western blot at 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ,g/mL.
Antibody validated: Western Blot in mouse samples and Immunohistochemistry in rat samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
ECRG2 Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
ECRG2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
SPINK7/ECRG2 (SPINK7)
(Serine Peptidase Inhibitor, Kazal Type 7 (SPINK7))
ECRG2 Antibody: The esophageal cancer-susceptibility gene 2 (ECRG2), also known as SPINK7, is a novel tumor suppressor gene identified from the human esophagus. It interacts directly with metallothionein 2A and urokinase-type plasminogen activator (uPA), and downregulates the activity of uPA, leading to reduced cancer cell migration, invasion and metastasis. ECRG2 forms a complex with uPA and its receptor uPAR, modifying the dynamic association of uPAR with beta1 integrins and disrupting the Src/MAP kinase pathway that normally stimulates cell migration and invasion. ECRG2 may thus represent a novel therapeutic target for cancer.